12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Other News

Teva, Actavis, Apotex, AstraZeneca, Novartis inflammation news

The U.S. District Court for the District of New Jersey ruled that AstraZeneca's U.S. Patent No. 6,598,603 covering asthma drug Pulmicort Respules budesonide is invalid. The court also ruled that ANDAs submitted by the generics companies to FDA for generic versions of Pulmicort Respules do not infringe AstraZeneca's U.S. Patent No. 7,524,834. The pharma filed the...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >